We hope our US readers enjoyed the long holiday weekend, and did your part to pursue happiness. We dodged raindrops on the Jersey Shore and took in the amazing action at Wimbledon (a condensed version of the fifth set is embedded above if you've got 20 minutes to kill), which oughtta qualify.
- The New York Times asks the hard questions about Genentech and Roche's Avastin, specifically, when does a drug's high cost and modest efficacy combine to make doctors and patients think twice about its worth?
- The Philly Inquirer notes that researchers writing in Nature Medicine are hoping that work in mice with tuberous sclerosis complex (TSC) holds the key to a variety of learning disorders.
- According to a Phase III study from Teva, doubling the dose of Copaxone doesn't result in better efficacy (though safety and tolerability didn't seem to be an issue).
- Investors apparently don't like German dialysis specialist Fresenius' proposed $3.7 billion acquisition of injectible products play APP, according to this Reuters report. The WSJ has the story here.
- Angiotech is spinning out its Taxus royalty stream and other assets into a new business with financing from Ares Management and New Leaf Venture Partners.